Dimensional Fund Advisors LP Boosts Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Dimensional Fund Advisors LP boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 5.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 550,806 shares of the company's stock after purchasing an additional 30,169 shares during the period. Dimensional Fund Advisors LP owned about 1.95% of Krystal Biotech worth $68,337,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in Krystal Biotech by 34.7% in the 4th quarter. BNP Paribas Financial Markets now owns 39,072 shares of the company's stock valued at $4,847,000 after acquiring an additional 10,057 shares in the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of Krystal Biotech by 103.6% in the fourth quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company's stock valued at $31,073,000 after purchasing an additional 127,435 shares in the last quarter. E Fund Management Co. Ltd. grew its holdings in shares of Krystal Biotech by 21.9% in the fourth quarter. E Fund Management Co. Ltd. now owns 4,495 shares of the company's stock valued at $558,000 after purchasing an additional 808 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech by 2.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 185,038 shares of the company's stock worth $22,956,000 after buying an additional 5,258 shares during the period. Finally, State of New Jersey Common Pension Fund D lifted its holdings in Krystal Biotech by 22.0% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 24,804 shares of the company's stock worth $3,077,000 after buying an additional 4,475 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company's stock, valued at $265,138,786.72. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CAO Kathryn Romano sold 8,087 shares of the company's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,719,041.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders sold 58,087 shares of company stock worth $9,493,191 over the last 90 days. Corporate insiders own 14.10% of the company's stock.

Krystal Biotech Trading Down 0.5 %

KRYS stock traded down $0.79 during trading on Friday, hitting $162.83. 144,963 shares of the company's stock were exchanged, compared to its average volume of 271,134. The business has a 50-day moving average price of $166.73 and a two-hundred day moving average price of $138.46. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 87.08 and a beta of 0.91. Krystal Biotech, Inc. has a 52-week low of $93.95 and a 52-week high of $189.97.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. The company's quarterly revenue was up 452400.0% on a year-over-year basis. During the same period last year, the firm posted ($1.76) EPS. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on KRYS. William Blair restated an "outperform" rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. HC Wainwright reaffirmed a "buy" rating and issued a $200.00 price target on shares of Krystal Biotech in a research report on Monday, May 6th. Citigroup lifted their price objective on Krystal Biotech from $160.00 to $195.00 and gave the company a "buy" rating in a research note on Tuesday, February 27th. Guggenheim upped their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $177.63.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).